Leading Pharma Company Partners Apollo Hospitals to Expand Multi-Cancer Detection Test in India; DII Stake Increases

On Monday, Indian benchmark indices traded higher in early trade. As of 9:40 AM, the Nifty 50 index was up 109.60 points, or 0.45 per cent, at 24,380.45. Amid the positive market sentiment,  Zydus Lifesciences share price traded at Rs 1,135.50, down 0.45 per cent despite the company announcing a strategic partnership to expand access to advanced cancer screening technologies in India. The stock had gained 3.71 per cent in the previous trading session following the announcement of the collaboration.

Zydus Signs MoU With Apollo Hospitals

Zydus Lifesciences has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to expand access to the Shield™ Multi-Cancer Detection (MCD) test across India. The initiative strengthens Zydus' exclusive partnership with Guardant Health Inc., a Nasdaq-listed precision oncology company, to commercialise the screening technology in the country.

The Shield MCD is a methylation-based blood test designed for individuals aged 45 years and above who are at average risk of cancer. Through a single blood draw, the test screens for 10 of the most common cancers, including bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian and pancreatic cancer.

FDA Breakthrough Device Designation

The company stated that the Shield MCD test has received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA), recognising its potential to provide more effective cancer screening than existing options. However, the company clarified that the designation does not constitute FDA approval, clearance or endorsement of the device's safety or effectiveness.

Addressing India's Cancer Burden

According to the company, cancer accounts for nearly 9 per cent of deaths related to non-communicable diseases in India. In 2022, more than 1.41 million people were diagnosed with cancer, while over 9 lakh deaths were reported. The company believes wider access to early screening can significantly improve early diagnosis and treatment outcomes.

Management Commentary

Speaking on this development, Dr Prathap C. Reddy, Chairman, Apollo Hospitals Group, said: "At Apollo, we have long believed that the most effective healthcare is proactive healthcare. The future of medicine lies not only in treating disease, but in preventing it and detecting it at its earliest, most treatable stages. Cancer continues to be one of the greatest health challenges facing societies worldwide, and expanding access to timely, reliable screening is critical to reducing its impact. Our collaboration with Zydus Lifesciences marks an important milestone in advancing accessible, patient-friendly cancer screening solutions for the people of India. By bringing together innovation, scientific excellence, and a shared commitment to better health outcomes, we can empower individuals to take charge of their health, enable earlier diagnosis, and significantly improve the chances of successful treatment. Together, we are taking another meaningful step toward a future where more lives are saved through early detection and timely intervention."

Dr Sharvil Patel, Managing Director, Zydus Lifesciences Ltd., said: "As India's leading oncology company, we are reimagining the role of diagnostics in cancer care. We are pleased to partner with Apollo Hospitals and Guardant Health to introduce Shield™ MCD in India, expanding access to an innovative screening technology that complements existing screening pathways. Through focused awareness initiatives, we continue to encourage timely screening and proactive healthcare with our range of companion diagnostics. By expanding access to precision diagnostics, we stand committed to unlocking new possibilities in patient care."
Also Read - Gautam Adani-Backed Defence Arm Announces Rs 2,500 Crore Investment in South Asia's Largest Private Missile Ecosystem

Zydus Lifesciences Shareholding Pattern

According to the latest March 2026 shareholding pattern, Foreign Institutional Investors (FIIs) reduced their stake by 0.11 percentage points to 6.95 per cent, while Domestic Institutional Investors (DIIs) increased their holding by 0.12 percentage points to 11.20 per cent.

About Zydus Lifesciences

Zydus Lifesciences Ltd is a global innovation-driven pharmaceutical company engaged in the discovery, development, manufacturing and marketing of medicines, vaccines, biologics and specialty healthcare products. The company operates across multiple therapeutic areas and has a presence in more than 50 countries.

With over 30,000 employees, including around 1,500 scientists engaged in research and development, Zydus continues to focus on innovation-led healthcare solutions. The company has developed several first-in-class therapies and precision healthcare technologies aimed at addressing unmet medical needs globally.

What are your thoughts on Zydus Lifesciences' partnership with Apollo Hospitals to expand multi-cancer screening in India? Share your views in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.